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Abstract
Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be
primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal
part of the fallopian tube.
Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination
chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to
show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to
serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear
cell adenocarcinoma.
The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological
agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a
monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated
positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of
molecular targeting drugs in patients with ovarian cancer are still underway.
Keywords: Review, ovarian cancer, conventional treatment, novel treatment, clear cell carcinoma, bevacizumab,
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Background
Ovarian cancer is the most lethal gynecologic malig-
nancy. The origin and pathogenesis of epithelial ovarian
cancer (EOC) have long been investigated but still
poorly understood. Studies have shown that epithelial
ovarian cancer is not a single disease but is composed
of a diverse group of tumors that can be classified based
on distinctive morphologic and molecular genetic fea-
tures [1].
Treatment of epithelial ovarian cancer (EOC) is based
on the combination of surgery and chemotherapy. Over
the past three decades, surgical tumor debulking, fol-
lowed by platinum-based chemotherapy is the standard
treatment for advanced ovarian cancer. Although
response rates and complete responses in advanced dis-
ease are >80% and 40-60%, respectively, after first-line
treatment with carboplatin and paclitaxel, most patients
will eventually relapse with a median progression-free
survival of 18 months [2]. Intraperitoneal chemotherapy
p o s s i b l yi m p r o v ep r o g r e s s i o n - f r e ea n do v e r a l ls u r v i v a l s
(PFS and OS), however, intraperitoneal chemotherapy
has not been universally accepted for at least three rea-
sons: toxic effects, intraperitoneal treatment delivery
issues and complications [3].
In this review, we first focus on the origin and patho-
genesis of EOC, introducing emerging concepts of a uni-
fying theory. Next we look at the history of treatment of
EOC as well as novel treatment strategies (e.g. molecular
targeted treatment).
Classification of epithelial ovarian cancer
Kurman et al. have proposed a dualistic model that cate-
gorizes various types of epithelial ovarian cancer into
two groups designated type I and type II [1,4,5]. Type I
tumors are clinically indolent and usually present at a
low stage, while type II tumors exhibit papillary, grandu-
lar, and solid patterns and are highly aggressive and
almost always present in advanced stage (Table 1). Type
I tumors include low-grade serous, low-grade endome-
trioid, clear cell and mucinous carcinomas and type II
include high-grade serous, high-grade endometrioid and
undifferentiated carcinomas. Malignant mixed mesoder-
mal tumors (carcinosarcomas) are included in the type
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tical to the pure type II carcinomas.
Type I and type II tumors have remarkably different
molecular genetic features as well as morphologic differ-
ences. For example, high-grade serous carcinoma (type
II tumor) is characterized by very frequent TP53 muta-
tions (> 80% of cases) and CCNE1 (encoding cyclin E1)
amplification but rarely has mutations that characterize
most type 1 I tumors such as KRAS, BRAF, ERBB2,
PTEN, CTNNB1, and PIK3CA [6]. In general, type I
tumors are genetically more stable than type II tumors
and display a distinctive pattern of mutations that occur
in specific cell types. Type II tumors which show greater
morphologic and molecular homogeneity are genetically
unstable and have a very high frequency of TP53 muta-
tions. These findings suggest that these two different
types of ovarian cancers develop along different molecu-
lar pathways.
In terms of origin of ovarian cancer, many of
researchers and gynecologic oncologists have tradition-
ally understood that the various different ovarian tumors
are all derived from the ovarian surface epithelium
(mesothelium) and that subsequent metaplastic changes
lead to the development of the different cell types
(Table 2). It is well known that serous, endometrioid,
clear cell, mucinous and transitional cell (Brenner) carci-
nomas morphologically resemble the epithelia of the fal-
lopian tube, endometrium, gastrointestinal tract or
endocervix and urinary bladder, respectively. The nor-
mal epithelial cells of the ovary, however, do not show
any resemblance with these tumors. An alternate theory
proposes that tumors with a mullerian phenotype (ser-
ous, endometrioid and clear cell) are derived from mul-
lerian-type tissue not mesothelium. It has been
suggested that they could arise from tissues ovarian
epithelial tumors are embryologically derived from the
mullerian duct [7]. This mullerian-type tissue (columnar
epithelium, often ciliated) forms cysts located in paratu-
bal and paraovarian locations. According to this theory,
ovarian tumors develop from these cysts, not the ovar-
ian surface epithelium. As the tumor enlarges, it com-
presses and eventually obliterates ovarian tissue
resulting in an adnexal tumor that appears to have
arisen in the ovary.
In summary, it appears that the vast majority of what
seem to be primary epithelial ovarian and primary peri-
toneal carcinomas are, in fact, secondary. Previous data
support the view that serous tumors develop from the
fimbria, the most distal part of the fallopian tube, endo-
metrioid and clear cell tumors from endometrial tissue
passing through the fallopian tube resulting in endome-
triosis and mucinous and Brenner tumors from transi-
tional-type epithelium located at the tubal-mesothelial
junction where the fimbria makes contact to the
peritoneum.
Although the data suggesting that epithelial ovarian
carcinoma arises in extra-ovarian sites and involves the
ovaries secondarily are compelling, low- and high-grade
serous carcinomas involve the ovaries and other pelvic
and abdominal organs, such as the omentum and
mesentery, much more extensively than the fallopian
tubes. Similarly, although endometrioid carcinomas
develop from endometriosis, which frequently involves
multiple sites in the pelvis, these tumors are usually
confined to the ovaries. It is likely that the predisposi-
tion for growth in the ovary is multifactorial but the
precise reasons for this are unknown.
The proposed model by assigning different epithelial
ovarian tumors into two categories based on clinical,
morphological, and molecular genetic characteristics
could serve as a framework for studying ovarian cancer
pathogenesis, but this model is not complete and does
not resolve all the issues. For example, clear cell carci-
noma and mucinous cadenocarcinoma are classified as
type I tumors, but unlike the other type I tumors clear
cell and mucinous cell types are often high-grade at pre-
sentation and show relatively strong resistance to plati-
num-based chemotherapy. This model does not replace
traditional histopathologic classification but can be
Table 1 Characteristics of type I and type II tumors
Type I Type II
Clinical features indolent aggressive
Histological
features
low-grade serous high-grade serous
low-grade
endometrioid
high-grade
endometrioid
clear cell undifferentiated
mucinous carcinosarcoma
Molecular features K-Ras TP53CCNE1
BRAF
ERBB2
PTEN
CTNNB1
PIK3CA
Table 2 Origin of ovarian carcinoma
Serous Endometrioid/Clear Mucinous/Brenner
Traditional theory ovarian surface epithelium (mesothelim) ovarian surface epithelium (mesothelim) ovarian surface epithelium (mesothelim)
Recent theory fimbria endometrial tissue (endometriosis) tubal-mesothelial junction
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events that play a role in the tumor progression and can
give light on new approaches to early detection and
treatment of ovarian cancer.
Conventional treatment of EOC
Early disease: FIGO stage I-II
Due to the lack of effective screening programs, ovarian
cancer is diagnosed at an early stage only in about 25%
of the cases. In most of these cases surgery is able to
cure the disease, and the five-year survival rate for early-
stage (stage I or II) ovarian cancer is around 90% [3].
Adjuvant chemotherapy for early stage ovarian cancer is
still controversial but some studies have shown its bene-
fit under confined conditions. According to the results
of two studies from the International Collaborative
Ovarian Neoplasm group and the EORTC, patients with
IA or IB FIGO stage, non-clear-cell histology, well-dif-
f e r e n t i a t e d( G 1 )t u m o r s ,a n da n“optimal” surgery (per-
formed according to international guidelines, with pelvic
and retroperitoneal assessment), appear not to benefit
from chemotherapy [8]. Thus, it is commonly believed
that, at least in these cases chemotherapy can be prob-
ably avoided and patients can be advised to undergo
clinical and instrumental follow-up. In all the other
(early stage) patients (adjuvant) chemotherapy is indi-
cated [3].
Advanced disease: FIGO III-IV
The standard treatment for patients with advanced ovar-
ian cancer is maximal surgical cytoreduction (total
abdominal hysterectomy, bilateral salpingo-oophorect-
omy, pelvic and para-aortic lymphadenectomy and
omentectomy) followed by systemic platinum-based che-
motherapy and, actually, is reasonable to expect a 5-year
survival for 10-30% of women diagnosed with ovarian
cancer at stage III or IV [3]. The concept of primary
debulking surgery is to diminish the residual tumor bur-
den to a point at which adjuvant therapy will be opti-
mally effective. The percentage of patients with
advanced ovarian cancer who can optimally undergo
cytoreductive surgery seems to range from 17%-87% [9],
depending on the report reviewed. This percentage can
largely depend on the experience of the surgeon.
Recently, an interesting randomized control trial on
treatment of advanced ovarian cancer was conducted
by Vergote et al. [10]. This phase III randomized
study compared primary debulking surgery followed
by chemotherapy with neoadjuvant chemotherapy fol-
lowed by interval debulking surgery in patients with
advanced ovarian cancer (Table 3). The median overall
survival was 29 months in the primary-surgery group
and 30 months in the neoadjuvant chemotherapy
group and this difference was not statistically signifi-
cant. Also, n difference was observed in median
p r o g r e s s i o n - f r e es u r v i v a l .T h e s er e s u l t sa r et h o r o u g h l y
discussed among the experts in this field; it is believed
that upfront maximal cytoreduction is still the stan-
dard, although further research should focus on how
to select patients that cannot receive optimal cytore-
duction and that can benefit from a neoadjuvant strat-
egy. When deciding debulking surgery, we should
assess predictive factors with respect to recidual
macroscopic disease after debulking surgery which is
the strongest independent variable in predicting survi-
val [10].
Recurrent disease
Despite the activity of first-line chemotherapy, which
gives response rates up to 80% in first line treatment,
the majority of patients die of their recurrent disease
[2]. Therefore, a large proportion of patients are candi-
dates for second-line treatment. Platinum sensitivity,
which is defined by a response to first-line platinum-
based therapy, has been found to predict the response
to subsequent retreatment with a platinum-containing
regimen frequently used for salvage therapy.
In general, patients who progress or have stable dis-
ease during first-line treatment or who relapse within 1
month are considered to be ‘platinum-refractory’.
Patients who respond to primary treatment and relapse
within 6 months are considered ‘platinum-resistant’, and
patients who relapse more than 6 months after comple-
tion of initial therapy are characterized as ‘platinum-sen-
sitive’ [11]. It is known that longer platinum free interval
(PFI) increases the chances for a benefit by platinum re-
challenge. This has been reported especially for PFI
longer than 12 months. Patients who are relapsing 6-12
months following the end of their initial regimen may
benefit less and are, usually classified as so-called ‘par-
tially sensitive’ [12] (Table 4).
Several randomized trials have been performed in pla-
tinum-sensitive patients. The ICON-4/OVAR 2.2 study
compared the combination chemotherapy (platinum
plus paclitaxel) to single chemotherapy (platinum alone)
in 802 patients with ‘platinum-sensitive’ relapsed ovarian
Table 3 Comparison of primary debulking surgery and
neoadjuvant chemotherapy
Primary debulking
surgery
Neoadjuvant
chemotherapy
Number of
patients
336 334
Age: Median
(range)
62 (25-86) 63 (33-81)
Stage 257 (76.5%) 253 (75.7%)
IIIc 77 (22.9%) 81 (24.3%)
IV 2 (0.6%) 0 (0%)
PFS 12 months 12 months
OS 29 months 30 months
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gression free survival were significantly longer in combi-
nation therapy compared to platinum alone [13].
The optimal treatment of patients with partially plati-
num-sensitive recurrent ovarian cancer is not clearly
defined. Trabectedin, a marine-derived antineoplastic
agent initially isolated from the tunicate Ecteinascidia
turbinate, has recently been introduced to this setting of
patients. This agent is currently produced synthetically
and its mechanism of anti-cancer action is based on
DNA minor-groove binding [14].
Patients with platinum refractory and resistant are
good candidates for novel investigational approaches
and studies of drug resistance. Single-agent therapy is
considered the standard treatment in these patients.
Low response rates are recorded in these patients with
the use of topotecan, docetaxel, oral stoposide, pegylated
liposomal doxorubicin (PLD), gemcitabine, ifosfamide
and hexamethylmelamine. The pegylated liposomal dox-
orubicin (PLD), a new formulation of doxorubicin, com-
pared with the conventional, assumes favorable
pharmacokinetic properties such as a lower plasma con-
centration peak, lower clearance, smaller distribution
volume, longer half-life and higher AUC, resulting in a
different and more convenient toxicity and efficacy pro-
file [15]. The efficacy of PLD has been clearly documen-
ted in recurrent ovarian cancer giving the rationale for
its use also in the first-line setting. The MITO-2 (Multi-
center Italian Trials in Ovarian cancer) phase III was
designed to compare the combinations of carboplatin
plus paclitaxel to an experimental arm with carboplatin
plus PLD in first-line treatment of ovarian cancer
patients. Results have been presented at ASCO 2010
showing that carboplatin plus PLD is not superior to
carboplatin plus paclitaxel in terms of PFS; the median
PFS was 19 and 16.8 months in the former and the lat-
ter arms, respectively. However, given the observed con-
fidence interval and the different toxicity profile it has
been proposed that carboplatin plus PLD could be con-
sidered an alternative to standard therapy [16].
Several randomized trials have been performed in pla-
tinum-sensitive patients. A multicenter phase III study,
recently published, the Calypso study [12], has com-
pared efficacy and safety of PLD-carboplatin and carbo-
platin-paclitaxel in 976 relapsed platinum-sensitive
ovarian cancer patients. The trial showed superiority of
the experimental arm in terms of PFS (11.3 months ver-
sus 9.4; HR = 0.821, 95% CI 0.72-0.94; P = 0.005). The
safety profile of PLD-carboplatin appears remarkably
different from that of carboplatin plus paclitaxel. The
PLD-carboplatin combination was associated with a
higher incidence of anemia and thrombocytopenia
(rarely requiring transfusions) and a higher incidence of
stomatitis and cutaneous toxicity (that were rarely
severe, 14% of G1-2). Notably, however, the PLD-carbo-
platin combination was associated with a very low inci-
dence of hair loss and neurotoxicity compared between
the 2 arms was found in terms of response rate [16].
One interesting observation of this trial was in PLD-car-
boplatin arm compared to carboplatin-paclitaxel there
was the reduction in the rate of hypersensitive reaction
(grade > 2: 5.6% versus 18.8%) Therapeutic Strategies in
Epithelial Ovarian Cancer and this is important informa-
tion since hypersensitive reactions are reported in the
general practice in patients treated with carboplatin up
to 25%.
Treatment of clear cell type of EOC
Although clear cell type is categorized in Type I (indo-
lent) ovarian cancer, it is known to show relatively
strong resistance to carboplatin and paclitaxel regimen
and thus poor prognosis compared to serous adenocar-
cinoma (SAC), especially in advanced stages. Previously
Sugiyama et al. investigated clinical characteristics of
clear cell carcinoma (CCC) of the ovary and showed
that patients with CCC were significantly more likely to
have FIGO Stage I disease than were patients with SAC
(48.5% versus 16.6%). However, a high recurrence rate
was noted in those patients with Stage IC CCC (37%)
and the survival rates for those stage IC CCC patients
were lower than those for patients with SAC. Also, the
3-year and 5-year survival rates for Stage III CCC
patients were significantly lower compared with Stage
III SAC patients [17].
Enomoto et al. demonstrated that clear cell or muci-
nous carcinoma histologic type did not respond to the
carboplatin-paclitaxel combination chemotherapy
(response rates 18%, 13%, respectively compared to 81%
for serous adenocarcinoma and 89% for endometrioid
adenocarcinoma) [18]. Considering those previous
reports, alternative chemotherapy regimens or novel
treatment for clear cell and mucinous carcinoma should
be investigated.
Takakura et al. performed phase II trial of paclitaxel-
carboplatin therapy (TC arm) versus irinotecan plus cis-
platin therapy (CPT-P arm) as first-line chemotherapy
for clear cell adenocarcinoma of the ovary [19]. PFS
Table 4 Association of platinum sensitivity and PFI
Platinum sensitivity resistant sensitive
refractory resistant partially sensitive sensitive
PFI during/immediately after chemotherapy < 6 months 6-12 months > 12 months
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ment groups. Because there were more patients with
large residual disease in the CPT-P arm, they performed
a subset analysis by removing those patients, and then
compared the PFS with that of patients without residual
disease less than 2 cm. The PFS tended to be longer in
the CPT-P group, although the difference was not statis-
tically significant. A phase III randomized trial of CPT-P
arm versus TC arm undertaken by JGOG (Japanese
Gynecologic Oncology Group) has closed and we are
waiting for the results. According to a small retrospec-
tive in Japan, gemcitabine showed modest activity and is
the most effective agent to clear cell adenocarcinoma of
the ovary [20].
History of chemotherapy regimens for EOC
Over the years, experts and research groups have
explored different combinations of antitumor drugs in
order to improve the prognosis of ovarian cancer (Table
5). In 1976, the report by Witshaw and Kroner on the
efficacy of cisplatin in ovarian cancer produced the
modern era of combination chemotherapy (platinum-
based combination therapy).
In the 1980s/early 1990 another turning point in the
treatment of ovarian cancer was related to the discovery
of paclitaxel, and active constituent of bark of the Pacific
Yew tree, Taxus brevifolia. This agent acts by promoting
microtubular assembly and stabilizes tubulin polymer
formation and has a great deal of activity in epithelial
ovarian cancer. Two randomized trials, the GOG 111
and the OV-10, comparing cisplatin/paclitaxel with cis-
platin/cyclophosphamide, showed additional clinical
benefit when cyclophosphamide was replaced by pacli-
taxel in the first-line setting [21-23].
Carboplatin, a cisplatin analogue is reported to have
fewer marked side effects, especially such toxicities as
nausea, renal toxicity, hearing loss, and neuromuscular
toxicities than cisplatin. The carboplatin-paclitaxel com-
bination is now considered an almost universal regimen
in the management of epithelial ovarian cancer, and
with a response rate of about 65%, PFS of 16-21 months
and an OS of 32-57 months it is the standard arm in all
the recent trials performed in this disease.
In the last two decades, some studies have been per-
formed in order to improve the efficacy of first-line che-
motherapy such as by delivering drugs in epithelial
ovarian cancer through the intraperitoneal (IP) route.
GOG 172 phase III trial revealed a prolonged survival
in the arm of intraperitoneal (IP) therapy compared to
the arm of intravenous (IV) therapy (65.6 and 49.7
months respectively; P = 0.03). Also PFS was better in
the IP-therapy arm than in the IV-therapy group (23.8
versus 18.3 months, P = 0.05) [24]. However, a signifi-
cantly higher rate of both hematologic and non-hemato-
logic toxicities, including catheter related complications
was observed in the arm of IP chemotherapy in this
study. In most countries the intravenous route of
administration of chemotherapy is still preferred.
Some studies have investigated the possibility to sub-
stitute paclitaxel with other drugs in order to improve
the efficacy of treatment and to reduce toxicities, in par-
ticular alopecia and neurotoxicity (Table 6) [25].
The first attempt to develop this strategy was per-
formed with docetaxel, a semisynthetic taxane with
pharmacologic and pharmacokinetic advantages, com-
pared to paclitaxel. This approach was sustained by
emerging evidences suggesting superiority over anthra-
cyclines and paclitaxel in metastatic breast cancer
[26,27].
In ovarian cancer, docetaxel demonstrated activity
[28], both in paclitaxel-resistant patients [29], and in
primary ovarian cancer, in association with carboplatin
[30]. To further investigate these promising findings, the
SCOTROC-1 phase III study was performed. 1077
patients with ovarian cancer were randomly assigned to
receive carboplatin IV (AUC 5) plus either docetaxel at
75 mg/m2 (1-h intravenous infusion) or paclitaxel at
175 mg/m2 (3-h intravenous infusion) [31]. Contrary to
the previous results from several preclinical studies,
which suggested that docetaxel might be more beneficial
to paclitaxel, this phase III study did not demonstrate a
survival advantage for carboplatin plus docetaxel over
carboplatin plus paclitaxel treatment.
Carboplatin plus paclitaxel combination was associated
with higher neurotxicity than carboplatin plus docetaxel
therapy. Conversely, treatment with carboplatin plus
docetaxel was associated with statistically more events
of G3-4 neutropenia (94% versus 84%, P<0.001) and
neutropenic complications than other treatment, requir-
ing the frequent use of G-CSF support. Based on these
data docetaxel with carboplatin has been considered a
possible alternative to carboplatin-paclitaxel treatment
in patients at very high risk of neurotoxicity, but has
not replaced carboplatin-paclitaxel as standard
treatment.
Table 5 The history of chemotherapy regimens for
ovarian cancer
Study Chemotherapy regimen Reference
GOG22 Melphalan < CA Cancer 51:783, 1983
GOG47 CA < CAP Cancer 57:1725, 1986
GOG52 CAP = CP JCO 7:457, 1989
GOG111 CP < TP NEJM 334:1, 1996
OV10 CP < TP JNCI 92:699, 2000
GOG158 TP = TC ASCO 1999; #1373, 1374
SCOTROC TC = DC ASCO 2002; #804
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was the most common drug used in clinical trials. Gem-
citabine-based combination therapy showed an average
response rate of 27.2%, and was the most common ther-
apy among the group of regimens with above average
response rate and progression-free survival.
Novel treatment strategies of EOC
The larger expectation for improved prognosis in EOC
is related to the use of the new biological agents. The
deeper knowledge of ovarian cancer biology has led to
the identification of multiple molecular targets, such as
growth factor receptors, signal transduction pathways,
cell cycle regulators, and angiogenic mechanisms. In this
section, we overlook the major two molecular targeted
agents applied to ovarian cancer treatment; anti-VEGF
antibody bevacizumab and PARP inhibitor Olaparib.
Bevacizumab
One of the most investigated and promising molecular
targeted drugs in ovarian cancer is bevacizumab, a
monoclonal antibody directed against VEGF. VEGF
expression is higher in ovarian cancer tumors than in
normal ovarian tissue or benign ovarian tumors, and
increasing VEGF expression in either cytosolic fractions
derived from ovarian cancer tumors or serum VEGF
levels in preoperative serum is considered to be asso-
ciated with advanced stage and worse survival.
In order to inhibit the VEGF pathway, there are two
primary strategies: (1) inhibition of the VEGF ligand with
antibodies or soluble receptors and (2) inhibition of the
VEGF receptor (VEGFR) with tyrosine kinase inhibitors
(TKIs), or receptor antibodies. Of the VEGF targeting
therapies, the most experience has been with a monoclo-
nal antibody that binds the VEGF ligand, known as beva-
cizumab (Avastin). Bevacizumab is a 149-kDa
recombinant humanized monoclonal IgG1 anti-VEGF
antibody. It has been FDA-1 approved for the treatment
of metastatic colorectal, breast, and non-small cell lung
cancer and shows promise in the treatment of ovarian
cancer. Several phase II studies have shown that bevaci-
zumab is active in recurrent ovarian cancer [33,34].
Two phase III trials (GOG218, ICON 7) have recently
evaluated the role of bevacizumab in first-line che-
motherapy as an adjunct to carboplatin and paclitaxel.
The GOG 218 is a multicenter, placebo-controlled trial
with the primary end point to determine whether the
addition of bevacizumab (15 mg/kg every 21 days) to
standard chemotherapy is able to prolong PFS after pri-
mary cytoreductive surgery. Recently bevacizumab plus
chemotherapy (carboplatin-paclitaxel) and bevacizumab
maintenance was demonstrated to be able to prolong
P F So fa b o u t4m o n t h s( 1 0 . 3m o n t h sv e r s u s1 4 . 1
months) compared to carboplatin-paclitaxel alone [35].
Another multicenter trial is the ICON 7, an open label,
two-arm trial, enrolling patients with high risk or
advanced (stage I-IV) epithelial ovarian cancer to receive
carboplatin plus paclitaxel or carboplatin-paclitaxel plus
bevacizumab given concurrently and as maintenance up
to 18 cycles. The bevacizumab used in this trial was half
of that given in the GOG 218 study. This trial also
showed that the addition of bevacizumab is able to pro-
long PFS compared to standard carboplatin-paclitaxel
[36].
Another study, OCEANS trial, showed that addition of
bevacizumab prolonged PFS in platinum-sensitive recur-
rent ovarian carcinoma cases [37].
PARP inhibitor, olaparib
The poly (ADP-ribose) polymerases (PARPs) are a large
family of multifunctional enzymes [38]. PARP-1, the
most abundant isoform, plays a key role in the repair of
DNA single-strand breaks through the repair of base
excisions. The inhibition of PARPs leads to the accumu-
lation of DNA single-strand breaks, which causes DNA
double-strand breaks at replication forks. These double-
strand breaks are repaired in normal cells mainly by the
error-free homologous recombination double-stranded
DNA repair pathway, in which essential components are
the tumor-suppressor proteins BRCA1 and BRCA2. In
the absent of either BRCA1 or BRCA2, these lesions are
not repaired, which results in cell cycle arrest and cell
death, although there is an alternate pathway to non-
homologous end-joining for DBS repair [39].
Table 6 Comparative investigations of the possibility to substitute paclitaxel with other drugs
Study Treatment arms FIGO stage n PFS (m) OS(m) p
SCOTROC-1 III-IV 0.71
Carboplatin (AUC5)+Paclitaxel (175 mg/mq) 539 14.8 N.A
Carboplatin (AUC5)+Docetaxel (75 mg/mq) 538 15.0 N.A
MITO-2 IC-IV N.S.
Carboplatin (AUC5) + Paclitaxel (175 mg/mq) 410 16.8 53.2
Carboplatin (AUC5) + Liposomal doxorubicin (30 mg/mq) 410 19.0 61.6
N.A.: not accessed
N.S.: not significant
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mosome 17q21 or BRCA2 on chromosome 13q31 are at
significantly higher risk of developing breast and ovarian
cancer than women in the control population. The life-
time risks of ovarian cancer are 54% for BRCA1 and
23% for BRCA2 mutation carriers [40]. Inherited muta-
tions in those genes are found in 5-10% of all ovarian
cancer patients. However, over 50% of high-grade serous
or undifferentiated carcinomas (Type II ovarian cancer)
showed loss of BRCA function, either by genetic or epi-
genetic events, which resulted in HR DNA repair defects
[41].
The discovery of epigenetic mechanism of BRCA1/2
germinal mutation and the association of this mutation
with ovarian cancer in 5-10% of the cases, led to the
therapeutic concept of “synthetic lethality” [42]. In fact,
in patients carriers BRCA mutation, PARP inhibition
results in unrepaired DNA single-strand and double
strand breaks and so cell death [43].
Fong et al. administered to fifty patients, the majority
of which were platinum refractory, the PARP inhibitor
olaparib with a favorable safety profile and a high
response rate, in particular in patients with BRCA muta-
tion. In patients with platinum-resistant and even plati-
num-refractory disease the response rate (of PARP
inhibitor, olaparib) was of 41.7% and 15.4%, respectively
[44]. Olaparib (AZD2281) was tested in BRCA-mutated
patients with ovarian, primary peritoneal, and fallopian
tube cancer. In the study, 20 patients (40%) responded
to the therapy. Currently, randomized trials of olaparib
and other PARP inhibitors in patients with ovarian can-
cer are underway.
Conclusion
Maximal surgical cytoreduction followed by systemic
taxane and platinum-based chemotherapy is the stan-
dard treatment for patients with ovarian cancer. Mole-
cular targeting therapy may improve the prognosis of
them.
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